Myeloid Sarcoma (Extramedullary AML)
A rare solid tumor formed by immature myeloid cells outside the bone marrow, closely related to acute myeloid leukemia and requiring systemic, leukemia-directed treatment.
- Tissue biopsy with myeloid markers
- Treated as systemic AML
- Access to transplant and trial options
- Most Common In
- Patients with AML history
- Common Sites
- Skin, Bone, Lymph Nodes
- Key Test
- Tissue Biopsy + Flow Cytometry
- Treatment Approach
- Systemic AML-Type Therapy
- Advanced Therapies
- Transplant, Targeted Agents, Trials
Condition Overview
Myeloid sarcoma, sometimes called granulocytic sarcoma or chloroma, is a rare tumor composed of immature myeloid cells growing outside the bone marrow, in tissues such as skin, lymph nodes, bone, or soft tissue. It can occur before, alongside, or after a diagnosis of acute myeloid leukemia (AML), and in some cases is the first sign of an underlying or relapsing AML.
Types and Presentations
Myeloid sarcoma can present in several clinical contexts.
Symptoms and Signs
Symptoms depend on the site involved and may be the first clue to an underlying myeloid malignancy.
Causes and Risk Factors
Myeloid sarcoma arises from the same abnormal myeloid clone that causes acute myeloid leukemia.
Diagnosis and Investigations
Diagnosis requires tissue confirmation, often combined with a full evaluation for bone marrow involvement.
Staging and Risk Groups
Myeloid sarcoma does not have its own staging system; instead, risk is assessed using the AML genetic and clinical risk framework, since treatment follows AML-directed pathways.
Standard Treatment
Because myeloid sarcoma reflects systemic disease, treatment generally mirrors standard AML therapy rather than localized treatment alone.
Advanced & Emerging Therapies
Targeted AML therapies are increasingly incorporated into myeloid sarcoma treatment based on the underlying genetic profile.
Targeted Therapy
FLT3 inhibitors
Used when FLT3 mutations are identified, in combination with chemotherapy.
Targeted Therapy
IDH1/IDH2 inhibitors
Considered for patients with IDH mutations, particularly in relapsed disease.
Cellular Therapy
Allogeneic stem cell transplant
Offers the best chance of durable remission for higher-risk or relapsed presentations.
Investigational Agent
Menin inhibitors and novel combinations
Being studied in trials for relapsed or genetically defined AML and myeloid sarcoma.
Biomarkers & Precision Medicine
The same molecular markers used in AML guide treatment selection in myeloid sarcoma.
When to Seek 2nd Opinion
Given how rare myeloid sarcoma is, expert pathology review and AML-specialist input are valuable.
Clinical Trials & Research
Prognosis & Outcomes
Prognosis in myeloid sarcoma is closely tied to the underlying AML genetic risk category rather than the extramedullary presentation itself.
Supportive Care
Supportive care addresses both the local effects of the mass and the systemic effects of AML-type treatment.
How CancerFax Helps You Explore Treatment Options
CancerFax helps you organize your biopsy and bone marrow results to clarify whether your myeloid sarcoma needs systemic AML therapy, local treatment, or both, and to identify specialist and trial options.
Get a free case reviewFrequently Asked Questions
Myeloid sarcoma is a rare tumor of immature myeloid cells that grows outside the bone marrow, in tissues such as skin, bone, or lymph nodes, and is closely related to acute myeloid leukemia.
It is considered an extramedullary manifestation of the same disease process as AML, and is generally treated with systemic leukemia-type therapy even when it appears as a localized mass.
A new lump under the skin, bone pain, or swollen lymph nodes are common first signs, sometimes occurring before any AML is found in the bone marrow.
Diagnosis requires a tissue biopsy with immunohistochemistry to confirm myeloid lineage, along with a bone marrow evaluation to check for concurrent AML.
Yes, it can present in isolation, but most patients are treated as having systemic AML given the high likelihood of marrow involvement over time.
Treatment typically follows AML-directed chemotherapy protocols, sometimes combined with local radiation therapy and, for higher-risk genetics, stem cell transplant.
Yes, mutations such as FLT3, IDH1/IDH2, NPM1, and TP53 found on the tissue or marrow sample guide which targeted therapies may be added to treatment.
Relapse can occur, sometimes presenting again as an extramedullary mass, which is why long-term monitoring after treatment is important.
Transplant is considered for patients with higher-risk genetic features or relapsed disease, based on the same criteria used in AML.
Yes. CancerFax can help you organize your biopsy and bone marrow reports for expert review, support a second opinion request, and help identify targeted therapy, transplant, or clinical trial options, including coordination with specialists internationally.
Take the Next Step in Your Myeloid Sarcoma Care
Send your biopsy and bone marrow reports to CancerFax for a structured review of your diagnosis and treatment options.